Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye

Clark Springs

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The objective of this review is to evaluate the safety and efficacy of polyethylene glycol 400/propylene glycol/hydroxypropylguar (Systane® Ultra [PEG/PG with HP-guar], Alcon Laboratories, Inc., Fort Worth, TX, USA) lubricant eye drops in reducing the signs and symptoms of dry-eye disease. Methods: A systematic literature search utilizing MEDLINE was conducted to identify peer-reviewed articles related to dry-eye disease and PEG/PG with HP-guar lubricant eye drops. The search covered the period prior to October 2009. Additionally, a manual search based on citations in the published literature was conducted. Results: The PEG/PG with HP-guar artificial tears shows in-vitro viscoelastic properties with pH optimization. The pH of the solution adjusts to the pH of the ocular surface upon instillation, which results in tear film elasticity and viscosity similar to that of subjects without dry-eye disease. The reviewed literature demonstrated that this delivery system showed a reduction in corneal and conjunctival staining in dry-eye disease, an improvement in tear film stability, a low coefficient of friction in an in-vitro model, and improved maintenance of best-corrected visual acuity over time. Conclusion: A few small-sized studies with short-term follow-up demonstrated that PEG/PG with HP-guar is a safe and effective lubricant eye drops for the treatment of dry-eye disease. Larger studies with longer duration are warranted to assess the longterm safety and efficacy of this formulation in patients with dry-eye disease.

Original languageEnglish
Pages (from-to)681-690
Number of pages10
JournalAdvances in Therapy
Volume27
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Eye Diseases
Cyamopsis
Tears
Safety
Propylene Glycol
Friction
Elasticity
Viscosity
MEDLINE
Visual Acuity
Signs and Symptoms
hydroxypropyl guar
Lubricant Eye Drops
Maintenance
Staining and Labeling

Keywords

  • Dry-eye disease
  • Eye drops
  • HP-guar
  • Systane
  • Tear film

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye. / Springs, Clark.

In: Advances in Therapy, Vol. 27, No. 10, 10.2010, p. 681-690.

Research output: Contribution to journalArticle

@article{31badfde62c4479ca9a6eee8a077590c,
title = "Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye",
abstract = "Objective: The objective of this review is to evaluate the safety and efficacy of polyethylene glycol 400/propylene glycol/hydroxypropylguar (Systane{\circledR} Ultra [PEG/PG with HP-guar], Alcon Laboratories, Inc., Fort Worth, TX, USA) lubricant eye drops in reducing the signs and symptoms of dry-eye disease. Methods: A systematic literature search utilizing MEDLINE was conducted to identify peer-reviewed articles related to dry-eye disease and PEG/PG with HP-guar lubricant eye drops. The search covered the period prior to October 2009. Additionally, a manual search based on citations in the published literature was conducted. Results: The PEG/PG with HP-guar artificial tears shows in-vitro viscoelastic properties with pH optimization. The pH of the solution adjusts to the pH of the ocular surface upon instillation, which results in tear film elasticity and viscosity similar to that of subjects without dry-eye disease. The reviewed literature demonstrated that this delivery system showed a reduction in corneal and conjunctival staining in dry-eye disease, an improvement in tear film stability, a low coefficient of friction in an in-vitro model, and improved maintenance of best-corrected visual acuity over time. Conclusion: A few small-sized studies with short-term follow-up demonstrated that PEG/PG with HP-guar is a safe and effective lubricant eye drops for the treatment of dry-eye disease. Larger studies with longer duration are warranted to assess the longterm safety and efficacy of this formulation in patients with dry-eye disease.",
keywords = "Dry-eye disease, Eye drops, HP-guar, Systane, Tear film",
author = "Clark Springs",
year = "2010",
month = "10",
doi = "10.1007/s12325-010-0052-3",
language = "English",
volume = "27",
pages = "681--690",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "10",

}

TY - JOUR

T1 - Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye

AU - Springs, Clark

PY - 2010/10

Y1 - 2010/10

N2 - Objective: The objective of this review is to evaluate the safety and efficacy of polyethylene glycol 400/propylene glycol/hydroxypropylguar (Systane® Ultra [PEG/PG with HP-guar], Alcon Laboratories, Inc., Fort Worth, TX, USA) lubricant eye drops in reducing the signs and symptoms of dry-eye disease. Methods: A systematic literature search utilizing MEDLINE was conducted to identify peer-reviewed articles related to dry-eye disease and PEG/PG with HP-guar lubricant eye drops. The search covered the period prior to October 2009. Additionally, a manual search based on citations in the published literature was conducted. Results: The PEG/PG with HP-guar artificial tears shows in-vitro viscoelastic properties with pH optimization. The pH of the solution adjusts to the pH of the ocular surface upon instillation, which results in tear film elasticity and viscosity similar to that of subjects without dry-eye disease. The reviewed literature demonstrated that this delivery system showed a reduction in corneal and conjunctival staining in dry-eye disease, an improvement in tear film stability, a low coefficient of friction in an in-vitro model, and improved maintenance of best-corrected visual acuity over time. Conclusion: A few small-sized studies with short-term follow-up demonstrated that PEG/PG with HP-guar is a safe and effective lubricant eye drops for the treatment of dry-eye disease. Larger studies with longer duration are warranted to assess the longterm safety and efficacy of this formulation in patients with dry-eye disease.

AB - Objective: The objective of this review is to evaluate the safety and efficacy of polyethylene glycol 400/propylene glycol/hydroxypropylguar (Systane® Ultra [PEG/PG with HP-guar], Alcon Laboratories, Inc., Fort Worth, TX, USA) lubricant eye drops in reducing the signs and symptoms of dry-eye disease. Methods: A systematic literature search utilizing MEDLINE was conducted to identify peer-reviewed articles related to dry-eye disease and PEG/PG with HP-guar lubricant eye drops. The search covered the period prior to October 2009. Additionally, a manual search based on citations in the published literature was conducted. Results: The PEG/PG with HP-guar artificial tears shows in-vitro viscoelastic properties with pH optimization. The pH of the solution adjusts to the pH of the ocular surface upon instillation, which results in tear film elasticity and viscosity similar to that of subjects without dry-eye disease. The reviewed literature demonstrated that this delivery system showed a reduction in corneal and conjunctival staining in dry-eye disease, an improvement in tear film stability, a low coefficient of friction in an in-vitro model, and improved maintenance of best-corrected visual acuity over time. Conclusion: A few small-sized studies with short-term follow-up demonstrated that PEG/PG with HP-guar is a safe and effective lubricant eye drops for the treatment of dry-eye disease. Larger studies with longer duration are warranted to assess the longterm safety and efficacy of this formulation in patients with dry-eye disease.

KW - Dry-eye disease

KW - Eye drops

KW - HP-guar

KW - Systane

KW - Tear film

UR - http://www.scopus.com/inward/record.url?scp=79952115135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952115135&partnerID=8YFLogxK

U2 - 10.1007/s12325-010-0052-3

DO - 10.1007/s12325-010-0052-3

M3 - Article

VL - 27

SP - 681

EP - 690

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 10

ER -